CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 115 enrolled
Drug / intervention
hepatectomy and transcatheter arterial chemoembolization +1 moreprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00652587
NCT00652587Phase 3Completed
CompareCT.gov

A Randomized Controlled Trial of Hepatectomy With Adjuvant Transcatheter Arterial Chemoembolization Versus Hepatectomy Alone for Stage IIIA Hepatocellular Carcinoma

Sun Yat-sen University·interventional·Posted Apr 3, 2008·Updated Apr 3, 2008

In Brief

A Phase 3 clinical trial evaluating hepatectomy and transcatheter arterial chemoembolization and hepatectomy for Hepatocellular Carcinoma and 2 related conditions. Completed, enrolled 115 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate whether hepatectomy combining with adjuvant transcatheter arterial chemoembolization (TACE) for Stage IIIA hepatocellular carcinoma (HCC) resulting better long-term survival outcome when compared with hepatectomy alone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatocellular Carcinoma, Hepatectomy, Chemoembolization
CountriesChina
CollaboratorsMinistry of Health, China

Timeline

Phase 3CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 3, 2008
Enrollment StartJan 1, 2002
Primary CompletionDec 1, 2007
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 18.2 years ago

Interventions

hepatectomy and transcatheter arterial chemoembolizationprocedure

partial hepatectomy with adjuvant transcatheter arterial chemoembolization

hepatectomyprocedure

hepatectomy alone